Direct inhibitors of InhA are active against Mycobacterium tuberculosis

Science Translational Medicine

Volumn 7, Issue 269, 2015, Pages

  Manjunatha, Ujjini H ^a,b   Rao, Srinivasa P S ^a   Kondreddi, Ravinder Reddy ^a   Noble, Christian G ^a   Camacho, Luis R ^a   Tan, Bee H ^a   Ng, Seow H ^a   Ng, Pearly Shuyi ^a   Ma, Ng L ^a   Lakshminarayana, Suresh B ^a   Herve, Maxime ^a   Barnes, Susan W ^c   Yu, Weixuan ^d   Kuhen, Kelli ^c   Blasco, Francesca ^a   Beer, David ^a   Walker, John R ^c   Tonge, Peter J ^d   Glynne, Richard ^c   Smith, Paul W ^a   Diagana, Thierry T ^a,b   more..

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 2 PYRIDONE DERIVATIVE; 4 HYDROXY 6 ISOBUTYL 3 PHENYLPYRIDIN 2(1H) ONE; ENZYME INHIBITOR; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; NITD 526; NITD 560; NITD 564; NITD 716; NITD 916; OXIDOREDUCTASE; PRETOMANID; PROTEIN INHA; PYRAZINAMIDE; PYRIDONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; 2,4-DIHYDROXYPYRIDINE; BACTERIAL PROTEIN; INHA PROTEIN, MYCOBACTERIUM; PYRIDINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; VOLUME OF DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOPHYSICS; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE; REPRODUCIBILITY; TUBERCULOSIS, MULTIDRUG-RESISTANT; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOPHYSICAL PHENOMENA; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; MICE, INBRED BALB C; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PYRIDINES; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84920711914     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010597     Document Type: Article

References (41)

1. World Health Organ ization (WHO), Global Tuberculosis Report (WHO Press, Geneva, 2012); http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf.
2. A. Zumla, P. Nahid, S. T. Cole, Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404 (2013).
3. S. V. Ramaswamy, R. Reich, S. J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua, E. A. Gra viss, Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47, 1241-1250 (2003).
4. L. Encinas, H. O'Keefe, M. Neu, M. J. Remuiñán, A.M. Patel, A. Guardia, C. P. Davie, N. Pérez-Macías, H. Yang, M. A. Convery, J. A.Messer, E. Pé rez-Herrán, P. A. Centrella, D. Alvarez-Gómez, M. A. Clark, S. Huss, G. K. O'Donovan, F. Ortega-Muro, W. McDowell, P. Castañeda, C. C. Arico-Muendel, S. Pajk, J. Rullás, I. Angulo-Barturen, E. Alvarez-Ruí z, A. Mendoza-Losana, L. Ballell Pages, J. Castro-Pichel, G. Evindar, Encoded library tec hnology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA. J. Med. Chem. 57, 1276-1288 (2014).
5. R . C. Hartkoorn, F. Pojer, J. A. Read, H. Gingell, J. Neres, O. P. Horlacher, K. H. Altmann, S. T. Cole, Pyridomycin bridges the NADH-and substrate-binding pockets of the enoyl reductase InhA. Nat. Chem. Biol. 10, 96-98 (2014).
6. P. Pan, P. J. Tonge, Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. Curr. Top. Med. Chem. 12, 672-693 (2012).
7. P. S. Shirude, P. Madhavapeddi, M. Naik, K. Murugan, V. Shinde, R. Nandishaiah, J. Bhat, A. Kumar, S. Hameed, G. Holdgate, G. Davies, H. McMiken, N. Hegde, A. Ambady, J. Venkatraman, M. Panda, B. Bandodkar, V. K. Sambandamurthy, J. A. Read, Methyl-thiazoles: A novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. J. Med. Chem. 56, 8533-8542 (2013).
8. J. B. Baell, G. A. Holloway, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010).
9. R. R. Kondreddi, U. H. Manjunatha, L. M. Ngai, S. Peukert, S. P. S. Rao, Pyridone derivatives and uses thereof in the treatment of tuberculosis, WO2014/093606 A1 (2014).
10. P. Ng, U. H. Manjunatha, S. P. S. Rao, L.R. Camacho, N. L. Ma, M. Herve, C. G. Noble, A. Goh, S. Peukert, T. T. Diagana, P. W. Smith, R. R. Kondreddi, Structure activity relationships of 4-hydroxy-2-pyridones: A novel anti-tuberculosis agents, unpublished material.
11. U. H. Manjunatha, H. Boshoff, C. S. Dowd, L. Zhang, T. J. Albert, J. E. Norton, L. Daniels, T. Dick, S. S. Pang, C. E. Barry III, Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 103, 431-436 (2006).
12. K. Andries, P. Verhasselt , J. Guillemont, H. W. Gö hlmann, J. M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, V. Jarlier, A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005).
13. M. M. Gutacker, B. Mathema, H. Soini, E. Shashkina, B. N. Kre iswirth, E. A. Graviss, J. M. Musser, Single-nucleotide polymorphism-based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. J. Infect. Dis. 193, 121-128 (2006).
14. C. E. Barry III R. E. Lee K. Mdluli A. E. Sampson B. G. Schroeder R. A. Slayden Y. Yuan Mycolic acids: Structure, biosynthesis and physiological functions. Prog. Lipid Res. 37 143-179 (1998).
15. C. Vilchè ze, W. R. Jacobs Jr., The mechanism of isoniazid killing: Clarity through the scope of genetics. Annu. Rev. Microbiol. 61, 35-50 (2007).
16. R. Rawat, A. Whitt y, P. J. Tonge, The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc. Natl. Acad. Sci. U.S.A. 100, 13881-13886 (2003).
17. C. Vilchè ze, F. Wang, M. Arai, M. H. Hazbón, R. Colangeli, L. Kremer, T. R. Weisbrod, D. Alland, J. C. Sacchettini, W. R. Jacobs Jr., Transfer of a point mutation in Mycobacterium tuberculosis i nhA resolves the target of isoniazid. Nat. Med. 12, 1027-1029 (2006).
18. J. Schiebel, A. Chang, S. Shah, Y. Lu, L. Liu, P. Pan, M. W. Hirschbeck, M. Tareilus, S. Eltschkner, W. Yu, J. E. Cummings, S. E. Knudson, G. R. Bommineni, S. G. Walker, R. A. Slayden, C. A. Sotriffer, P. J. Tonge, C. Kisker, Rational design of broad-spectrum antibacterial activity based on a clinically relevant enoyl-ACP r eductase inhibitor. J. Biol. Chem. 289, 15987-16005 (2014).
19. P. Pan, S. E. Knudson, G. R. Bommineni, H. J. Li, C. T. Lai, N. Liu, M. Garcia-Diaz, C. Simmerling, S. S. Patil, R. A. Slayden, P. J. Tonge, Time-dependent diaryl ether inhibitors of InhA: Structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy. ChemMedChem 9, 776-791 (2014).
20. D. A. Rozwarski, C. Vilch èze, M. Sugantino, R. Bittman, J. C. Sacchettini, Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J. Biol. Chem. 274, 15582-15589 (1999).
21. J. S. Freundlich, F. Wang, C. Vilchèze, G. Gulten, R. Langley, G. A. Schiehser, D. P. Jacobus, W. R. Jacobs Jr., J. C. Sacchettini, Triclos an derivatives: Towards potent inhibitors of drugsensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem 4, 241-248 (2009).
22. X. He, A. Alian, R. Stroud, P. R. Ortiz de Montellano, Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J. Med. Chem. 49, 6308-6323 (2006).
23. T. J. Sullivan, J. J. Truglio, M. E. Bo yne, P. Novichenok, X. Zhang, C. F. Stratton, H. J. Li, T. Kaur, A. Amin, F. Johnson, R. A. Slayden, C. Kisker, P. J. Tonge, High affinity InhA inhibitors with activity against drug-resistant strains of Mycobac terium tuberculosis. ACS Chem. Biol. 1, 43-53 (2006).
24. R. C. Hartkoorn, C. Sala, J. Neres, F. Pojer, S. Magnet, R. Mukherjee, S. Uplekar, S. Boy-Rottger, K. H. Altmann, S. T. Cole , Towards a new tuberculosis drug: Pyridomycin-Nature's isoniazid. EMBO Mol. Med. 4, 1032-1042 (2012).
25. Food and Drug Administration, Guidance for Industry-Pulmonary Tuberculosis: Developing Drugs for Treatment; www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM373580.pdf.
26. S. P. Rao, S. B. Lakshminarayana, R. R. Kondreddi, M. Herve, L. R. Camacho, P. Bifani, S. K. Kalapala, J. Jiricek, N. L. Ma, B. H. Tan, S. H. Ng, M. Nanjundappa, S. Ravindran, P. G. Seah, P. Thayalan, S. H. Lim, B. H. Lee, A. Goh, W. S. Barnes, Z. Chen, K. Gagaring, A. K. Chat t erjee, K. Pethe, K. Kuhen, J. Walker, G. Feng, S. Babu, L. Zhang, F. Blasco, D. Beer, M. Weaver, V. Dartois, R. Glynne, T. Dick, P. W. Smith, T. T. Diagana, U. H. Manjunatha, Indolcarboxamid e is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci. Transl. Med. 5, 214ra168 (2013).
27. P. J. Tonge, C. Kisker, R. A. Slayden, Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. Curr. Top. Med. Chem. 7, 489-498 (2007).
28. A. Qué mard, J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. R. Jacobs Jr., J. S. Blanchard, Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochem. 34, 8235-8241 (1995).
29. T. Heimbach, D. M. Oh, L. Y. Li, M. Forsberg, J. Savolainen, J. Leppanen, Y. Matsunaga, G. Flynn, D. Fleisher, Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res. 20, 848-856 (2003).
30. H. Guo, Q. Seet, S. Denkin, L. Parsons, Y. Zhang, Molecular characterization of isoniazidresistant clinical isolates of Mycobacterium tuberculosis from the USA. J. Med. Microbiol. 55, 1527-1531 (2006).
31. J. A. Leeds, M. Sachdeva, S. Mullin, S. W. Barnes, A. Ruzin, In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxom icin or vancomycin. J. Antimicrob. Chemother. 69, 41-44 (2014).
32. R. A. Slayden, C. E. Barry III, Analysis of the lipids of Mycobacterium tuberculosis. Methods Mol. Med. 54, 229-245 (2001).
33. S. Parikh, D. P. Moynihan, G. Xiao, P. J. Tonge, Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 38, 13623-13634 (1999).
34. S. L. Parikh, G. Xiao, P. J. Tonge, Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39, 7645-7650 (2000).
35. T. G. Battye L. Kontogiannis O. Johnson H. R. Powell A. G. Leslie iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67 271-281 (2011).
36. P. Evans, Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72-82 (2006).
37. V. Molle, G. Gulten, C. Vilchèze, R. Veyron-Churlet, I. Zanella-Clé on, J. C. Sacchettini, W. R. Jacobs Jr., L. Kremer, Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis. Mol. Microbiol. 78, 1591-1605 (2010).
38. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
39. G. N.Murshudov, P. Skubá k, A. A. Lebedev,N. S. Pannu, R. A. Steiner, R. A. Nicholls, M. D. Winn, F. Long, A. A. Vagin, REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
40. B. Faller, J. Wang, A. Zimmerlin, L. Bell, J. Hamon, S. Whitebread, K. Azzaoui, D. Bojanic, L. Urban, High-throughput in vitro profiling assays: Lessons learnt from experiences at Novartis. Expert Opin. Drug Metab. Toxicol. 2, 823-833 (2006).
41. B. Faller, Artificial membrane assays to assess permeability. Curr. Drug Metab. 9, 886-892 (2008).